Ignite Creation Date:
2024-05-06 @ 6:41 PM
Last Modification Date:
2024-10-26 @ 2:53 PM
Study NCT ID:
NCT05759546
Status:
RECRUITING
Last Update Posted:
2024-02-06
First Post:
2023-02-26
Brief Title:
PARP Inhibitor With CDK46 Inhibitor and Endocrine Therapy in HR HER2-Advanced Breast Cancer
Sponsor:
Fudan University
Organization:
Fudan University
Study Overview
Official Title:
PARP Inhibitor in Combination With CDK46 Inhibitor and Endocrine Therapy as the First-line Therapy for HR HER2-Advanced Breast Cancer
Status:
RECRUITING
Status Verified Date:
2023-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a prospective open-label phase II clinical study for patients with HRHER2- advanced breast cancer
Detailed Description:
Patients with SNF3 subtype of HRHER2- advanced breast cancer confirmed by the Department of Pathology and Key Laboratory of Breast Cancer of Fudan University Affiliated Cancer Hospital are planned to be enrolled The main purpose is to evaluate efficacy of PARP inhibitor in SNF3 subtype of HRHER2- advanced breast cancer and prepare for subsequent randomized controlled phase III clinical studies with larger sample size
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None